Gordion Bioscience

Startup

Transforming Cancer Drug Development

At Gordion, we're addressing one of the biggest hurdles in oncology drug development: the high failure rate of clinical trials. Most trials fail because traditional pre-clinical models, like cell lines or animal studies, don’t accurately reflect how human tumors behave.

To solve this, we developed a platform that selects the optimal tissue and genetic background for cancer drug targets. By identifying key response and resistance biomarkers, our platform helps choose the most relevant pre-clinical models—using data exclusively derived from patient tumors. This approach ensures far greater accuracy and relevance than relying on multiple cell lines that often poorly predict real tumor behavior. By integrating patient-specific data early in the process, we significantly increase the chances of clinical success and reduce trial failures

website